Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 3 for:    hcverso3
Previous Study | Return to List | Next Study

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01830127
First received: March 22, 2013
Last updated: October 23, 2014
Last verified: October 2014
  Purpose

To assess the pharmacokenetic characteristics of 600 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected patients with mild hepatic impairment (CPA) (Arm 1) versus 400 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected patients with moderate hepatic impairment (CPB) (Arm 2).


Condition Intervention Phase
Hepatitis C, Chronic
Drug: Ribavirin
Drug: BI 207127 high dose
Drug: Faldaprevir
Drug: BI 207127 low dose
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase IIb Open Label Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Patients With Moderate Hepatic Impairment (Child-Pugh B) With Genotype 1b Chronic Hepatitis C Infection

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • SVR12: Plasma HCV RNA level less than 25 IU/mL at 12 weeks after End of Treatment [ Time Frame: 12 weeks after End of Treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • SVR4: Plasma HCV RNA level less than 25 IU/mL at 4 weeks after End of Treatment [ Time Frame: 4 weeks after End of Treatment ] [ Designated as safety issue: No ]

Enrollment: 35
Study Start Date: April 2013
Study Completion Date: October 2014
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: cohort A CPA
Cohort A CPA BI 207127/QD Faldaprevir Ribavirin
Drug: Ribavirin
24 Weeks
Drug: Faldaprevir
24 Weeks
Drug: BI 207127 low dose
24 Weeks
Experimental: cohort A CPB
Cohort B CPB BI 207127/QD Faldaprevir Ribavirin
Drug: BI 207127 high dose
24 Weeks
Drug: Ribavirin
24 Weeks
Drug: Faldaprevir
24 Weeks

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Treatment naïve and treatment experienced patients (prior relapse, interferon intolerant, and [allowed in Cohort A only] prior partial response).
  2. Chronic HCV infection of genotype 1 (GT1), sub-GT1b virus only.
  3. Liver cirrhosis defined as Metavir Grade=4 or Ishak Grade =5 on liver biopsy or liver stiffness of =13 kPa on fibroscan.

Exclusion criteria:

  1. HCV infection of mixed genotype (1/2, 1/3, and 1/4) or mixed sub-GT1a/1b or undefined diagnosed by genotypic testing at screening
  2. Liver disease due to causes other than chronic HCV infection which may include but is not limited to hemochromatosis, Wilson's disease, or autoimmune liver diseases.
  3. HIV infection
  4. Patients who have been previously treated with an investigational or approved DAA
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01830127

Locations
United States, California
1241.30.10003 Boehringer Ingelheim Investigational Site
La Mesa, California, United States
1241.30.10007 Boehringer Ingelheim Investigational Site
San Diego, California, United States
United States, Florida
1241.30.10001 Boehringer Ingelheim Investigational Site
Deland, Florida, United States
1241.30.10012 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida, United States
United States, Texas
1241.30.10011 Boehringer Ingelheim Investigational Site
Arlington, Texas, United States
United States, Virginia
1241.30.10002 Boehringer Ingelheim Investigational Site
Norfolk, Virginia, United States
Germany
1241.30.49005 Boehringer Ingelheim Investigational Site
Berlin, Germany
1241.30.49004 Boehringer Ingelheim Investigational Site
Berlin, Germany
1241.30.49002 Boehringer Ingelheim Investigational Site
Berlin, Germany
1241.30.49008 Boehringer Ingelheim Investigational Site
Bonn, Germany
1241.30.49006 Boehringer Ingelheim Investigational Site
Frankfurt am Main, Germany
1241.30.49001 Boehringer Ingelheim Investigational Site
Hannover, Germany
1241.30.49003 Boehringer Ingelheim Investigational Site
Leipzig, Germany
1241.30.49007 Boehringer Ingelheim Investigational Site
Mainz, Germany
Spain
1241.30.34002 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1241.30.34005 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1241.30.34003 Boehringer Ingelheim Investigational Site
Madrid, Spain
1241.30.34001 Boehringer Ingelheim Investigational Site
Majadahonda (Madrid), Spain
United Kingdom
1241.30.44002 Boehringer Ingelheim Investigational Site
London, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01830127     History of Changes
Other Study ID Numbers: 1241.30, 2012-003534-17
Study First Received: March 22, 2013
Last Updated: October 23, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Spain: Spanish Agency of Medicines
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Ribavirin
Anti-Infective Agents
Antimetabolites
Antiviral Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014